GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

dusquetide   Click here for help

GtoPdb Ligand ID: 14001

Synonyms: IMX942 | SGX942
Compound class: Peptide
Comment: Dusquetide is a first-in-class innate defense regulator (IDR) that modulates the innate human immune response by binding to sequestosome 1 (p62) [1]. It is effective in the treatment of bacterial infections, acting by modulating the inflammatory response and improving bacterial clearance, rather than having direct antibacterial activity [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC[C@H](C)C(C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)N
Isomeric SMILES CC[C@H](C)C(C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)N
InChI InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1
InChI Key ZUJBBVJXXYRPFS-OUROWQTJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
In August 2025, following a review of Phase 2 clinical results (NCT06386744), the USA FDA granted Orphan Drug Designation to dusquetide for the treatment of oral and genital ulcers caused by Behçet's disease. In addition, a Phase 3 clinical study (NCT03237325), to evaluate dusquetide as a treatment for oral mucositis in patients undergoing chemotherapy for head and neck cancer, has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03237325 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Phase 3 Interventional Soligenix
NCT06386744 Dusquetide for the Treatment of Behcet's Disease Phase 2 Interventional Soligenix